A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
作者信息
Messali Serena, Bertelli Anna, Campisi Giovanni, Zani Alberto, Ciccozzi Massimo, Caruso Arnaldo, Caccuri Francesca
机构信息
Section of Microbiology Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy.
出版信息
J Med Virol. 2021 Dec;93(12):6468-6470. doi: 10.1002/jmv.27247. Epub 2021 Aug 10.
Abstract
摘要
相似文献
1
A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.意大利出现的新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）B.1.621谱系集群以及病毒分离株对BNT162b2疫苗的敏感性。
J Med Virol. 2021 Dec;93(12):6468-6470. doi: 10.1002/jmv.27247. Epub 2021 Aug 10.
2
Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.BNT162b2 疫苗接种者血清对 SARS-CoV-2 变异株的中和作用。
Viruses. 2021 Oct 6;13(10):2011. doi: 10.3390/v13102011.
3
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
4
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
5
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
6
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.新型冠状病毒感染及一剂BNT162b2疫苗接种后对变异株的中和反应
N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036. Epub 2021 Apr 7.
7
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
8
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.BNT162b2诱导的针对新型严重急性呼吸综合征冠状病毒2刺突变异体的中和作用。
N Engl J Med. 2021 Jul 29;385(5):472-474. doi: 10.1056/NEJMc2106083. Epub 2021 May 12.
9
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
10
Neutralizing Activity of BNT162b2-Elicited Serum.BNT162b2诱导血清的中和活性
N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.
引用本文的文献
1
Uncovering the Binding Mechanism of Mutated Omicron Variants via Computational Strategies.通过计算策略揭示变异奥密克戎毒株的结合机制
ACS Omega. 2025 Jan 13;10(3):2790-2798. doi: 10.1021/acsomega.4c08562. eCollection 2025 Jan 28.
2
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.原型和 BA.5 蛋白纳米颗粒疫苗可预防叙利亚仓鼠感染奥密克戎 BA.5 变异株。
J Virol. 2024 Mar 19;98(3):e0120623. doi: 10.1128/jvi.01206-23. Epub 2024 Feb 2.
3
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies.SARS-CoV-2 变异株的进化：对免疫逃逸、疫苗接种、治疗和诊断策略的影响。
Viruses. 2023 Apr 10;15(4):944. doi: 10.3390/v15040944.
4
Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants.SARS-CoV-2 变异株 Mu 的非系统性报告偏倚可能会影响我们对新兴变异株的流行病学动态的理解。
Genome Biol Evol. 2023 Apr 5;15(4). doi: 10.1093/gbe/evad052.
5
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.2019冠状病毒病最新情况：严重急性呼吸综合征冠状病毒2变种、抗病毒药物及疫苗
Heliyon. 2023 Mar;9(3):e13952. doi: 10.1016/j.heliyon.2023.e13952. Epub 2023 Feb 23.
6
Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.在哥伦比亚新冠疫情的四个流行高峰期间，灭活全病毒疫苗和基因疫苗引发的针对主要新冠病毒变异株的中和抗体反应
Vaccines (Basel). 2022 Dec 14;10(12):2144. doi: 10.3390/vaccines10122144.
7
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体、当前的新冠疫苗及其对2019冠状病毒病（COVID-19）的治疗意义
Vaccines (Basel). 2022 Sep 16;10(9):1538. doi: 10.3390/vaccines10091538.
8
A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.一种产生 VFLIP-X 刺突的环状 mRNA 疫苗原型通过小鼠血清赋予了对 SARS-CoV-2 变体的广泛中和作用。
Antiviral Res. 2022 Aug;204:105370. doi: 10.1016/j.antiviral.2022.105370. Epub 2022 Jun 27.
9
Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种的中药化合物对宿主免疫系统的挽救作用的计算研究
Pharmaceuticals (Basel). 2022 Jun 13;15(6):741. doi: 10.3390/ph15060741.
10
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.mRNA-1273 和 Ad26.COV2.S 疫苗可预防 SARS-CoV-2 的 B.1.621 变体。
Med. 2022 May 13;3(5):309-324.e6. doi: 10.1016/j.medj.2022.03.009. Epub 2022 Apr 15.
本文引用的文献
1
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2.新冠病毒 B.1.621 变异株的特征描述。
Infect Genet Evol. 2021 Nov;95:105038. doi: 10.1016/j.meegid.2021.105038. Epub 2021 Aug 14.
2
New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.新型严重急性呼吸综合征冠状病毒2变体——对临床、公共卫生及疫苗的影响
N Engl J Med. 2021 May 13;384(19):1866-1868. doi: 10.1056/NEJMc2100362. Epub 2021 Mar 24.
Zotero 插件